Company: BLRX
Filing Date: 2025-05-23
Form Type: 6-K
Source: 0001178913-25-001939
Chunk: 0

Company: BioLineRx Ltd.
Filing Date: 2025-05-23
Form: 6-K
Chunk 0
---
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-35223 _______________________ BioLineRx Ltd. (Translation of registrant’s name into English) _______________________ 2 HaMa’ayan Street
Modi’in 7177871, Israel (Address of Principal Executive Offices) _______________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐ BioLineRx Ltd. (the “ Registrant”) announces that it will hold an Annual Meeting of Shareholders on June 29, 2025, at 3:00 p.m. (Israel time), at the Registrant’s office, Modi’in Technology Park, 2 HaMa’ayan Street, Modi’in 7177871, Israel. The Notice of Annual General Meeting and Proxy Statement, the related proxy card and voting instruction form for holders of American Depositary Shares are attached to this Report on Form 6-K as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and incorporated herein by reference.

| Exhibit No. 
 99.1        | BioLineRx Ltd. Notice and Proxy Statement for the Annual Geneal Meeting of Shareholders to be held 
 on June 29, 2025                                                                                   |
|:------------|:---------------------------------------------------------------------------------------------------|
| 99.2        | Form of Proxy Card                                                                                 |
| 99.3        | Form of Voting Instruction Form                                                                    |

This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| BioLineRx Ltd. |                         |
| By:            | /s/ Philip A. Serlin    |
|                | Philip A. Serlin        |
|                | Chief Executive Officer |

Dated: May 23, 2025